ABSTRACT
Patent ductus arteriosus is a common problem in premature neonates, especially in low– birth weight neonates with a reported incidence rate of 30%. Indomethacin and ibuprofen are the common pharmacological treatment options for Patent Ductus Arteriosus (PDA) closure. However, oral paracetamol has been used as an alternative treatment. In this study, we aimed to describe patients’ demographic characteristics, review primary and secondary outcomes, and review the safety profile. We studied retrospectively from 2012 to 2015 by retrieving medical records from the electronic Health Information System (eHIS) of Hospital Sungai Buloh. A total of 55 neonates were reviewed and 52 were included for the analysis. The results of the analysis indicated that there was no significant increase in demographic characteristics, PDA closure rates, and primary and secondary outcomes in neonates who received both treatments. The PDA closure rate was 60% and 64% in the PCM and indomethacin groups, respectively. In conclusion, oral PCM may be used as an alternative first-line treatment in the management of PDA with less contraindication issues.
